-$0.54 Earnings Per Share Expected for Aptinyx Inc (APTX) This Quarter

Share on StockTwits

Equities analysts expect Aptinyx Inc (NASDAQ:APTX) to announce ($0.54) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Aptinyx’s earnings. The business is scheduled to announce its next quarterly earnings results before the market opens on Thursday, March 21st.

According to Zacks, analysts expect that Aptinyx will report full-year earnings of ($2.70) per share for the current financial year, with EPS estimates ranging from ($2.74) to ($2.66). For the next fiscal year, analysts expect that the company will report earnings of ($2.24) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Aptinyx.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Aptinyx from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Swann cut their price target on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, January 17th. JPMorgan Chase & Co. downgraded shares of Aptinyx from an “overweight” rating to a “neutral” rating and cut their price target for the company from $30.00 to $8.00 in a report on Thursday, January 17th. BMO Capital Markets cut their price target on shares of Aptinyx to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 18th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $40.00 price target on shares of Aptinyx in a report on Monday, December 3rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aptinyx currently has an average rating of “Buy” and a consensus target price of $18.80.

In other news, Director Robert J. Hombach bought 25,000 shares of the stock in a transaction that occurred on Friday, January 25th. The shares were acquired at an average cost of $5.53 per share, for a total transaction of $138,250.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Ashish Khanna bought 10,000 shares of the stock in a transaction that occurred on Friday, January 18th. The stock was purchased at an average price of $5.45 per share, for a total transaction of $54,500.00. The disclosure for this purchase can be found here. Insiders purchased a total of 36,050 shares of company stock worth $198,284 over the last quarter.

Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN acquired a new position in Aptinyx in the 3rd quarter valued at $185,000. Vanguard Group Inc. grew its stake in Aptinyx by 371.0% in the 3rd quarter. Vanguard Group Inc. now owns 296,717 shares of the company’s stock valued at $8,593,000 after buying an additional 233,717 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new position in Aptinyx in the 3rd quarter valued at $775,000. BlackRock Inc. grew its stake in Aptinyx by 1,822.7% in the 3rd quarter. BlackRock Inc. now owns 769,072 shares of the company’s stock valued at $22,272,000 after buying an additional 729,072 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Aptinyx in the 3rd quarter valued at $973,000. Institutional investors and hedge funds own 63.11% of the company’s stock.

Shares of Aptinyx stock traded down $0.08 during midday trading on Wednesday, reaching $4.01. 351,000 shares of the company’s stock traded hands, compared to its average volume of 398,341. Aptinyx has a 52 week low of $3.90 and a 52 week high of $32.25.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Read More: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.